Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: Results of the VECTOR study

Current Medical Research and Opinion

Volumn 27, Issue 7, 2011, Pages 1367-1374

  Hassanein, Mohamed ^a   Hanif, Wasim ^b   Malik, Waqar ^c   Kamal, Ali ^b   Geransar, Parnia ^d   Lister, Nicola ^d   Andrews, Chris ^d   Barnett, Anthony ^b,c  

^a BETSI CADWALADR UNIVERSITY HEALTH BOARD   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^d Novartis Pharmaceuticals UK Ltd   (United Kingdom)

Author keywords

Diabetes mellitus; Dipeptidyl peptidase 4 inhibitors; Fasting hypoglycaemia; Muslims; Type 2; Vildagliptin

Indexed keywords

GLICLAZIDE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; METFORMIN; METFORMIN PLUS VILDAGLIPTIN; VILDAGLIPTIN;

ADD ON THERAPY; ADULT; AGED; ARTICLE; ASTHMA; BODY WEIGHT; COHORT ANALYSIS; CONFIDENCE INTERVAL; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; HYPOGLYCEMIA; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MOSLEM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PROSPECTIVE STUDY; TREATMENT OUTCOME; VALVULAR HEART DISEASE;

ADAMANTANE; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FASTING; FEMALE; GLICLAZIDE; HUMANS; HYPOGLYCEMIC AGENTS; ISLAM; MALE; METFORMIN; MIDDLE AGED; NITRILES; PYRROLIDINES; SULFONYLUREA COMPOUNDS; TIME FACTORS;

EID: 79958777288     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.579951     Document Type: Article

References (25)

1. Salti I, Benard E, Detournay B, et al. A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: results of the epidemiology of diabetes and Ramadan 1422/2001 (EPIDIAR) study. Diabetes Care 2004;27:2306-11. (Pubitemid 39281377)
2. Al-Arouj M, Assaad-Khalil S, Buse J, et al. Recommendations for management of diabetes during Ramadan: update 2010. Diabetes Care 2010; 33:1895-902.
3. Hanif MW, Valsamakis G, Dixon A, et al. Detection of impaired glucose tolerance and undiagnosed type 2 diabetes in UK South Asians: an effective screening strategy. Diabetes Obes Metab 2008;10:755-62.
4. Al-Arouj M, Bouguerra R, Buse J, et al. Recommendations for management of diabetes during Ramadan. Diabetes Care 2005;28:2305-11. (Pubitemid 41242487)
5. Hui E, Bravis V, Hassanein M, et al. Management of people with diabetes wanting to fast during Ramadan. BMJ 2010;340:c3053.
6. Hassanein MM. Diabetes and Ramadan: how to achieve a safer fast for Muslims with diabetes. Br J Diab Vasc Dis 2010;10:246-50.
7. Bravis V, Hui E, Salih S, et al. Ramadan Education and Awareness in Diabetes (READ) programme for Muslims with Type 2 diabetes who fast during Ramadan. Diabet Med 2010;27:327-31.
8. Devendra D, Gohel B, Bravis V, et al. Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan. Int J Clin Pract 2009; 63:1446-50.
9. Ferrannini E, Fonseca V, Zinman B, et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009; 11:157-66.
10. Matthews DR, Dejager S, Ahré n B, et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab 2010;12:780-9.
11. National Institute for Health and Clinical Excellence. Clinical guideline 87 - Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes (short guideline), 2009. Available at: http://www.nice.org.uk/nicemedia/live/ 12165/44318/44318.pdf [Last accessed 17 November 2010].
12. Ahré n B, Foley JE. The islet enhancer vildagliptin: mechanisms of improved glucose metabolism. Int J Clin Pract Suppl 2008;62(S159):8-14.
13. Ahré n B, Pacini G, Tura A, et al. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes. Horm Metab Res 2007; 39:826-9.
14. Pratley RE, Schweizer A, Rosenstock J, et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naive patients: analysis of pooled vildagliptin monotherapy database. Diabetes Obes Metab 2008;10:931-8.
15. Utzschneider KM, Tong J, Montgomery B, et al. The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care 2008;31:108-13.
16. Ahré n B, Pacini G, Foley JE, et al. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005;28:1936-40.
17. Mari A, Sallas WM, He YL, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005;90:4888-94. (Pubitemid 41159387)
18. Ahré n B, Schweizer A, Dejager S, et al. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab 2009;94:1236-43.
19. Amiel SA, Dixon T, Mann R, et al. Hypoglycaemia in Type 2 diabetes. Diabet Med 2008;25:245-54. (Pubitemid 351322690)
20. Bosi E, Dotta F, Jia Y, et al. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatmentnaive patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009; 11:506-15.
21. Goodman M, Thurston H, Penman J. Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Horm Metab Res 2009;41:368-73.
22. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29:1963-72. (Pubitemid 44156663)
23. Foley JE, Jordan J. Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience. Vasc Health Risk Manag 2010; 6:541-8.
24. Keating GM. Vildagliptin: a review of its use in type 2 diabetes mellitus. Drugs 2010;70:2089-112.
25. Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 2005;28:2948-61 (Pubitemid 43942931)